FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

• Published in: Drug resistance updates Vol. 53; p. 100719
• Main Authors: Drożdżal, Sylwester, Rosik, Jakub, Lechowicz, Kacper, Machaj, Filip, Kotfis, Katarzyna, Ghavami, Saeid, Łos, Marek J.
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.12.2020; Published by Elsevier Ltd
• Subjects: Animals; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - metabolism; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - metabolism; Antimalarials - administration & dosage; Antimalarials - metabolism; Antiviral Agents - administration & dosage; Antiviral Agents - metabolism; Chloroquine; Clinical Trials as Topic - methods; Coronavirus; COVID-19 - metabolism; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors - administration & dosage; Cytochrome P-450 CYP3A Inhibitors - metabolism; Drug Approval - methods; Drug Therapy, Combination; Humans; Hydroxychloroquine - administration & dosage; Hydroxychloroquine - metabolism; Lopinavir; Remdesivir; Ribavirin; Ritonavir; SARS-CoV-2; SARS-CoV-2 - drug effects; SARS-CoV-2 - metabolism; United States - epidemiology; United States; SARS-CoV-2; Coronavirus; Ritonavir; Chloroquine; Lopinavir; Remdesivir; Ribavirin

In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, c...